CULTURED AFB DRUG RESISTANT DR MYCOBACTERIUM ANTI-TUBERCULAR DST RAPID 15 DRUGS PANEL Test
Test Name: CULTURED AFB DRUG RESISTANT DR MYCOBACTERIUM ANTI-TUBERCULAR DST RAPID 15 DRUGS PANEL Test
Components:
- Streptomycin
- Isoniazid
- Rifampicin
- Ethambutol
- Pyrazinamide
- Clofazimine
- Ethionamide
- Capreomycin
- Kanamycin
- Amikacin
- PAS
- Cycloserine
- Levofloxacin
- Moxifloxacin
- Linezolid
Price: 3810.0 AED
Sample Condition: Submit pure growth of Mycobacterium tuberculosis complex on appropriate media in sterile screw capped container in a sealed plastic bag. Ship refrigerated OR when used with other AFB culture or Mycobacteria identification tests, the pure growth obtained in the laboratory from specimens already submitted will be processed for Antitubercular sensitivity.
Report Delivery: Sample Daily by 3.30 pm; Report 21 days
Method: Automated Fluorescent
Test Type: Tuberculosis
Doctor: Physician
Test Department:
Pre Test Information: No special preparation required
Test Details
The CULTURED AFB DRUG RESISTANT (DR MYCOBACTERIUM) ANTI-TUBERCULAR DST RAPID 15 DRUGS PANEL test is a diagnostic test used to determine the drug resistance profile of Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB). This test is performed on a culture of Mycobacterium tuberculosis obtained from a patient’s sputum or other clinical specimen. The culture is grown in the laboratory and then exposed to 15 different anti-tubercular drugs. The purpose of this test is to determine which drugs the bacteria are resistant to, as well as which drugs they are susceptible to.
The test involves the use of various techniques, such as the proportion method, the agar dilution method, or the molecular-based method (such as the line probe assay or the Xpert MTB/RIF test), to assess the growth of the bacteria in the presence of different concentrations of the drugs. The drugs included in the panel typically cover a wide range of anti-tubercular drugs, including first-line drugs (such as isoniazid, rifampicin, and ethambutol) and second-line drugs (such as fluoroquinolones and injectable agents).
The results of the test will indicate which drugs the Mycobacterium tuberculosis strain is resistant to, which drugs it is susceptible to, and which drugs it may have intermediate susceptibility to. This information is crucial for guiding the appropriate treatment regimen for patients with drug-resistant TB.
Overall, the CULTURED AFB DRUG RESISTANT (DR MYCOBACTERIUM) ANTI-TUBERCULAR DST RAPID 15 DRUGS PANEL test is an important tool in the management of drug-resistant tuberculosis, helping to inform treatment decisions and improve patient outcomes.
| Test Name | CULTURED AFB DRUG RESISTANT DR MYCOBACTERIUM ANTI-TUBERCULAR DST RAPID 15 DRUGS PANEL Test |
|---|---|
| Components | *Streptomycin *Isoniazid*Rifampicin *Ethambutol*Pyrazinamide *Clofazimine *Ethionamide*Capreomycin*Kanamycin *Amikacin*PAS*Cycloserine *Levofloxacin*Moxifloxacin*Linezolid |
| Price | 3810.0 AED |
| Sample Condition | Submit pure growth of Mycobacterium tuberculosis complex on appropriate media in sterile screw capped container in a sealed plastic bag.Ship refrigerated OR when used with other AFB culture or Mycobacteria identification tests, the pure growth obtained in the laboratory from specimens already submitted will be processed for Antitubercular sensitivity. |
| Report Delivery | Sample Daily by 3.30 pm; Report 21 days |
| Method | Automated Fluorescent |
| Test type | Tuberculosis |
| Doctor | Physician |
| Test Department: | |
| Pre Test Information | No special preparation required |
| Test Details |
The CULTURED AFB DRUG RESISTANT (DR MYCOBACTERIUM) ANTI-TUBERCULAR DST RAPID 15 DRUGS PANEL test is a diagnostic test used to determine the drug resistance profile of Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB). This test is performed on a culture of Mycobacterium tuberculosis obtained from a patient’s sputum or other clinical specimen. The culture is grown in the laboratory and then exposed to 15 different anti-tubercular drugs. The purpose of this test is to determine which drugs the bacteria are resistant to, as well as which drugs they are susceptible to. The test involves the use of various techniques, such as the proportion method, the agar dilution method, or the molecular-based method (such as the line probe assay or the Xpert MTB/RIF test), to assess the growth of the bacteria in the presence of different concentrations of the drugs. The drugs included in the panel typically cover a wide range of anti-tubercular drugs, including first-line drugs (such as isoniazid, rifampicin, and ethambutol) and second-line drugs (such as fluoroquinolones and injectable agents). The results of the test will indicate which drugs the Mycobacterium tuberculosis strain is resistant to, which drugs it is susceptible to, and which drugs it may have intermediate susceptibility to. This information is crucial for guiding the appropriate treatment regimen for patients with drug-resistant TB. Overall, the CULTURED AFB DRUG RESISTANT (DR MYCOBACTERIUM) ANTI-TUBERCULAR DST RAPID 15 DRUGS PANEL test is an important tool in the management of drug-resistant tuberculosis, helping to inform treatment decisions and improve patient outcomes. |
